Project Grant 2303792
Award Date
8/1/23
Completion Date
7/31/24
Dollars Obligated
$273K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,991 to Saber Therapeutics, Inc. will support the development of a new approach to deliver cancer-killing proteins specifically to acute myeloid leukemia (AML) cells while sparing healthy cells. The project aims to engineer natural killer (NK) cells with targeted protein degraders (TPDs) against three common AML driver proteins. The resulting NK-TPD cells will be tested for...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...
This $274,975 Small Business Innovation Research (SBIR) Phase I grant awarded by the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) supports the development of an antibody therapy targeting neoantigens in acute myeloid leukemia (AML). The project aims to create a platform technology that combines cancer-specific antibodies and adoptive natural killer (NK) immune cells to achieve high efficacy and low toxicity in treating relapsed/refractory AML. Key...
This Project Grant award of $305,000 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development and validation of a novel platform for targeted cancer therapies by Redpoint Oncology, Inc. The project aims to create new cancer treatments designed to selectively target and destroy therapy-resistant cancer cells, addressing a critical unmet medical need. Key research objectives include designing and testing new payload...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $303,864 to Core Biotherapeutics Inc. aims to develop a platform for disruptive drug candidates that can reprogram molecular networks to produce therapeutic effects beyond single-target approaches. The key objectives are to: 1) demonstrate that oligonucleotide drug efficacy is a function of transcription factor (TF) network reprogramming using a breast cancer cell line, 2) build a...
This $305,000 Small Business Innovation Research (SBIR) Phase I project awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) aims to develop a new class of gene therapies delivered more safely, cost-effectively, and at scale for serious genetic disorders. The project leverages short oligonucleotides conjugated with small molecules to induce proximity of endogenous epigenetic machinery to disease-relevant genes,...
The National Science Foundation (NSF) awarded a $295,000 Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Theracea Pharma LC, a for-profit small business, to develop 18F-radiotracer kits for detection of biomarkers using positron emission tomography (PET). This SBIR Phase I project aims to create innovative diagnostic tools to enhance healthcare quality and improve patient outcomes, particularly in the field of oncology. The products will assist...
This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...
This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...